Market-Moving News for June 21st
Market-Moving News for June 21st
SRPT: 45% | Sarepeta Therapeutics shares are trading higher after the company announced FDA approval of an expansion to the labeled indication for ELEVIDYS to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. Also, multiple firms raised their respective price targets on the stock.
SRPT：45％ | Sarepeta Therapeutics的股價走高，此前該公司宣佈美國食品藥品管理局批准擴大ELEVIDYS的標記適應症，將年齡至少爲4歲的杜興氏肌肉萎縮症已證實存在DMD基因突變的患者包括在內。此外，多家公司提高了各自的股票目標股價。
CLOV: 13% | Clover Health shares are trading higher following the purchase of 877,567 shares by a company director.
CLOV：13％ | 在公司董事購買了877,567股股票之後，三葉草健康的股價走高。
NVNO: 16% | EnVVeno Medical shares are trading higher after the company reported interim venous ulcer healing data from the SAVVE U.E. pivotal trial for VenoValve, which will be presented at the Society for Vascular Surgery 2024 Annual Meeting.
NVNO：16％ | EnvVeno Medical的股價上漲，此前該公司公佈了SAVVE美國VenoValve關鍵試驗的中期靜脈潰瘍癒合數據，該試驗將在2024年血管外科學會年會上公佈。